• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Passage Bio Inc. (Amendment)

    5/29/24 4:35:50 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PASG alert in real time by email
    SC 13D/A 1 d842540dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

    TO RULE 13d-2(a)

    (Amendment No. 2)*

     

     

    PASSAGE BIO, INC.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    702712100

    (CUSIP Number)

    Versant Venture Capital VI, L.P.

    Max Eisenberg

    One Sansome Street, Suite 1650

    San Francisco, CA 94104

    415-801-8100

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 24, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP No. 702712 100    13D

     

    1.   

    Name of Reporting Persons

     

    Versant Venture Capital VI, L.P.

    2.   

    Check the Appropriate Box if a Member of a Group (see instructions)

    (a) ☐  (b) ☒(1)

     

    3.   

    SEC USE ONLY

     

    4.   

    Source of Funds (see instructions)

     

    WC

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ☐

    6.   

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power

     

    4,026,417 shares of common stock (2)

       8.   

    Shared Voting Power

     

    0

       9.   

    Sole Dispositive Power

     

    4,026,417 shares of common stock (2)

       10.   

    Shared Dispositive Power

     

    0

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,026,417 shares of common stock (2)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row 11

     

    6.5% (3)

    14.   

    Type of Reporting Person (see instructions)

     

    PN

     

     

    (1)

    This Schedule 13D is filed by Versant Venture Capital VI, L.P. (“Versant VI”), Versant Ventures VI GP, L.P. (“GP VI”), Versant Ventures VI GP-GP, LLC (“LLC VI”), Versant Vantage I, L.P. (“Vantage LP”), Versant Vantage I GP, L.P. (“Vantage GP”), Versant Vantage I GP-GP, LLC (“Vantage LLC” and, with Versant VI, GP VI, LLC VI, Vantage LP and Vantage GP, collectively, the “Reporting Persons”). LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI. Vantage LLC is the general partner of Vantage GP, which is the general partner of Vantage LP. Each of Vantage LLC and Vantage GP share voting, investment and dispositive power over the shares held by Vantage LP. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI.

    (3)

    The percentages used herein are calculated based upon 61,640,596 shares issued and outstanding as of May 9, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q for the quarter ended March 31, 2024, filed with the United States Securities and Exchange Commission (the “SEC”) on May 14, 2024 (the “Form 10-Q”).

     

    2


    CUSIP No. 702712 100    13D

     

    1.   

    Name of Reporting Persons

     

    Versant Ventures VI GP, L.P.

    2.   

    Check the Appropriate Box if a Member of a Group (see instructions)

    (a) ☐  (b) ☒(1)

     

    3.   

    SEC USE ONLY

     

    4.   

    Source of Funds (see instructions)

     

    AF

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ☐

    6.   

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power

     

    0

       8.   

    Shared Voting Power

     

    4,026,417 shares of common stock (2)

       9.   

    Sole Dispositive Power

     

    0

       10.   

    Shared Dispositive Power

     

    4,026,417 shares of common stock (2)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,026,417 shares of common stock (2)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row 11

     

    6.5% (3)

    14.   

    Type of Reporting Person (see instructions)

     

    PN

     

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI.

    (3)

    The percentages used herein are calculated based upon 61,640,596 shares outstanding as of May 9, 2024, as set forth in the Form 10-Q.

     

    3


    CUSIP No. 702712 100    13D

     

    1.   

    Name of Reporting Persons

     

    Versant Ventures VI GP-GP, LLC

    2.   

    Check the Appropriate Box if a Member of a Group (see instructions)

    (a) ☐  (b) ☒(1)

     

    3.   

    SEC USE ONLY

     

    4.   

    Source of Funds (see instructions)

     

    AF

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ☐

    6.   

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power

     

    0

       8.   

    Shared Voting Power

     

    4,026,417 shares of common stock (2)

       9.   

    Sole Dispositive Power

     

    0

       10.   

    Shared Dispositive Power

     

    4,026,417 shares of common stock (2)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,026,417 shares of common stock (2)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row 11

     

    6.5% (3)

    14.   

    Type of Reporting Person (see instructions)

     

    OO

     

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI.

    (3)

    The percentages used herein are calculated based upon 61,640,596 shares outstanding as of May 9, 2024, as set forth in the Form 10-Q.

     

    4


    CUSIP No. 702712 100    13D

     

    1.   

    Name of Reporting Persons

     

    Versant Vantage I, L.P.

    2.   

    Check the Appropriate Box if a Member of a Group (see instructions)

    (a) ☐  (b) ☒(1)

     

    3.   

    SEC USE ONLY

     

    4.   

    Source of Funds (see instructions)

     

    WC

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ☐

    6.   

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power

     

    0 shares of common stock (2)

       8.   

    Shared Voting Power

     

    0

       9.   

    Sole Dispositive Power

     

    0 shares of common stock (2)

       10.   

    Shared Dispositive Power

     

    0

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 shares of common stock (2)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row 11

     

    0.0% (3)

    14.   

    Type of Reporting Person (see instructions)

     

    PN

     

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Vantage LP. Vantage LLC is the general partner of Vantage GP, which is the general partner of Vantage LP. Each of Vantage LLC and Vantage GP share voting, investment and dispositive power over the shares held by Vantage LP.

    (3)

    The percentages used herein are calculated based upon 61,640,596 shares outstanding as of May 9, 2024, as set forth in the Form 10-Q.

     

    5


    CUSIP No. 702712 100    13D

     

    1.   

    Name of Reporting Persons

     

    Versant Vantage I GP, L.P.

    2.   

    Check the Appropriate Box if a Member of a Group (see instructions)

    (a) ☐  (b) ☒(1)

     

    3.   

    SEC USE ONLY

     

    4.   

    Source of Funds (see instructions)

     

    AF

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ☐

    6.   

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power

     

    0

       8.   

    Shared Voting Power

     

    0 shares of common stock (2)

       9.   

    Sole Dispositive Power

     

    0

       10.   

    Shared Dispositive Power

     

    0 shares of common stock (2)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 shares of common stock (2)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row 11

     

    0.0% (3)

    14.   

    Type of Reporting Person (see instructions)

     

    PN

     

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Vantage LP. Vantage LLC is the general partner of Vantage GP, which is the general partner of Vantage LP. Each of Vantage LLC and Vantage GP share voting, investment and dispositive power over the shares held by Vantage LP.

    (3)

    The percentages used herein are calculated based upon 61,640,596 shares outstanding as of May 9, 2024, as set forth in the Form 10-Q.

     

    6


    CUSIP No. 702712 100    13D

     

    1.   

    Name of Reporting Persons

     

    Versant Vantage I GP-GP, LLC

    2.   

    Check the Appropriate Box if a Member of a Group (see instructions)

    (a) ☐  (b) ☒(1)

     

    3.   

    SEC USE ONLY

     

    4.   

    Source of Funds (see instructions)

     

    AF

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ☐

    6.   

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power

     

    0

       8.   

    Shared Voting Power

     

    0 shares of common stock (2)

       9.   

    Sole Dispositive Power

     

    0

       10.   

    Shared Dispositive Power

     

    0 shares of common stock (2)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 shares of common stock (2)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row 11

     

    0.0% (3)

    14.   

    Type of Reporting Person (see instructions)

     

    OO

     

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Vantage LP. Vantage LLC is the general partner of Vantage GP, which is the general partner of Vantage LP. Vantage LLC and Vantage GP share voting, investment and dispositive power over the shares held by Vantage LP.

    (3)

    The percentages used herein are calculated based upon 61,640,596 shares outstanding as of May 9, 2024, as set forth in the Form 10-Q.

     

    7


    CUSIP No. 702712 100    13D

     

    Explanatory Note: This Amendment No. 2 (this “Amendment”) amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on March 13, 2020, as amended by Amendment No. 1 filed with the Commission on November 9, 2023 (collectively, the “Original Schedule 13D”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

    Item 5. Interest in Securities of the Issuer

    Solely on behalf of, and only to the extent that it relates to the Reporting Persons, Item 5 of the Original Schedule 13D is hereby amended as follows:

    (a) and (b) See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person.

    (c) On May 24, 2024, Vantage LP sold 933,352 shares of Common Stock at a weighted average price per share of $1.1005 for aggregate proceeds of approximately $1,027,153.88.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    May 29, 2024

     

    Versant Venture Capital VI, L.P.
    By:   Versant Ventures VI GP, L.P.
    Its:   General Partner
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:   /s/ Max Eisenberg, Chief Operating Officer
    Versant Ventures VI GP, L.P.
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:   /s/ Max Eisenberg, Chief Operating Officer
    Versant Ventures VI GP-GP, LLC
    By:   /s/ Max Eisenberg, Chief Operating Officer
    Versant Vantage I, L.P.
    By:   Versant Vantage I GP, L.P.
    Its:   General Partner
    By:   Versant Vantage I GP-GP, LLC
    Its:   General Partner
    By:   /s/ Max Eisenberg, Chief Operating Officer
    Versant Vantage I GP, L.P.
    By:   Versant Vantage I GP-GP, LLC
    Its:   General Partner
    By:   /s/ Max Eisenberg, Chief Operating Officer
    Versant Vantage I GP-GP, LLC
    By:   /s/ Max Eisenberg, Chief Operating Officer
    Get the next $PASG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PASG

    DatePrice TargetRatingAnalyst
    11/29/2024$3.00 → $4.00Outperform
    Wedbush
    9/3/2024$7.00Buy
    Rodman & Renshaw
    3/8/2022Overweight → Neutral
    JP Morgan
    3/4/2022$29.00 → $24.00Outperform
    Raymond James
    1/19/2022$29.00 → $6.00Buy → Neutral
    Goldman
    7/1/2021$29.00Outperform
    Raymond James
    More analyst ratings

    $PASG
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Passage Bio Inc.

      SCHEDULE 13D/A - Passage BIO, Inc. (0001787297) (Subject)

      4/25/25 7:48:26 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Passage Bio Inc.

      DEFA14A - Passage BIO, Inc. (0001787297) (Filer)

      4/16/25 7:01:31 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Passage Bio Inc.

      DEF 14A - Passage BIO, Inc. (0001787297) (Filer)

      4/16/25 7:00:29 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Financials

    Live finance-specific insights

    See more
    • Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

      Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partnership opportunities for clinical-stage pediatric lysosomal storage disease programs including GM1 gangliosidosisManagement to host a webcast presentation to review interim FTD data today at 8:30 a.m. ET

      12/20/23 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

      Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β-Gal activity and GM1 gangliosides, similar to healthy controlsDose 2 biomarker responses demonstrated durability up to 12 months after treatmentImagine-1 study participants showed initial evidence of improved survival relative to natural history dataTreated first patient at highest dose level, Dose 3, in July; initial safety and biomarker data from Dose 3 expected by mid-2024Management to host a conference call and webcast today at 8:30 a.m. ET

      8/7/23 7:00:12 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

      Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023Planned expansion of Imagine-1 study to treat patients at a higher dose; expect to dose first patient in second half of 2023Plan to report initial safety and biomarker data from Cohort 1 of global upliFT-D trial for frontotemporal dementia in the second half of 2023Ended 2022 with strong cash position; cash runway into the first half of 2025Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, March 06, 2023 (GLOBE NEW

      3/6/23 7:00:41 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

      Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative d

      3/4/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio to Participate in Upcoming Investor Conferences

      PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Wednesday, March 5, 2025Presentation Time: 9:10 a.m. ETLocation: Boston, MA Leerink Global Biopharma Conference Format: Management will participate in a presentation and investor meetingsDate: Wednesday, March 12, 2025Presentation Time: 8:00 a.m. ETLocation: Miami, FL A live web

      2/26/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

      PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN and FTD-C9orf72 patients to allow for dose exploration and support regulatory strategy Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Completed process development and scale-up of a high-productivity, suspension-based manufacturing process for PBFT02 Extended cash runway into 1Q 2027 by moving to outsourc

      1/10/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $78,731 worth of shares (235,572 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/24/25 5:38:49 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $49,704 worth of shares (149,054 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/17/25 6:10:47 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO Borthwick Kathleen

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      3/18/25 5:12:20 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Passage Bio Inc.

      SC 13G - Passage BIO, Inc. (0001787297) (Subject)

      11/14/24 12:03:11 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Passage Bio Inc.

      SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)

      8/9/24 7:06:55 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Passage Bio Inc.

      SC 13G/A - Passage BIO, Inc. (0001787297) (Subject)

      8/9/24 5:15:23 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush resumed coverage on Passage BIO with a new price target

      Wedbush resumed coverage of Passage BIO with a rating of Outperform and set a new price target of $4.00 from $3.00 previously

      11/29/24 7:25:55 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Passage BIO with a new price target

      Rodman & Renshaw initiated coverage of Passage BIO with a rating of Buy and set a new price target of $7.00

      9/3/24 8:12:19 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio downgraded by JP Morgan

      JP Morgan downgraded Passage Bio from Overweight to Neutral

      3/8/22 5:15:06 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Leadership Updates

    Live Leadership Updates

    See more
    • Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

      Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines comp

      11/13/24 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Welcomes Tom Kassberg to Board of Directors

      PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission

      9/10/24 7:52:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

      Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-2024Expect to present initial safety and biomarker data from Cohort 1 in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 202

      8/7/23 7:15:54 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lynx1 Capital Management Lp bought $241,038 worth of shares (373,645 units at $0.65) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      12/31/24 4:05:36 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $146,665 worth of shares (259,998 units at $0.56) and bought $137,855 worth of shares (196,355 units at $0.70) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      11/27/24 6:11:20 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care